Potential of albumin nanoparticles as carriers for interferon gamma

Drug Development and Industrial Pharmacy

Volumn 31, Issue 3, 2005, Pages 271-280

  Segura, Sara ^a   Espuelas, Socorro ^a   Renedo, María Jesús ^a   Irache, Juan Manuel ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Albumin; Immunotherapy; Interferon gamma; Nanoparticles

Indexed keywords

ALBUMIN; CYTOKINE; DRUG CARRIER; NANOPARTICLE; NITRIC OXIDE; RECOMBINANT GAMMA INTERFERON;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ELECTRICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE SPECTROSCOPY; HELA CELL; HUMAN; HUMAN CELL; MACROPHAGE; MECHANICAL STRESS; PH MEASUREMENT; STEADY STATE;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; INTERFERON TYPE II; MACROPHAGES; MICE; NANOSTRUCTURES;

EID: 16244375268     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-52063     Document Type: Article

References (33)

1. Arnedo, A., Espuelas, S., & Irache, J. M. (2002). Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. International Journal of Pharmaceutics, 244, 59-72.
2. Badaro, R., Falcoff, E., & Badaro, F. S. (1990). Treatment of visceral leishmaniasis with pentavalent antimony and interferon-gamma. New England Journal of Medicine, 322, 16-21.
3. Boteva, R., Zlateva, T., Dorovska-Taran, V., Visser, A. J. W. G., Tsanev, R., & Salvato, B. (1996). Dissociation equilibrium of human recombinant interferon gamma. Biochemistry, 35, 14825-14830.
4. Geland, J. L., & Jones, A. J. S. (1996). Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable microspheres. Pharmaceutical Research, 13, 1462-1473.
5. Eppstein, D. A., Marsh, Y. V., van der Pas, M., Feigner, P. L., & Schreiber, A. B. (1985). Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. Proceedings of the National Academy of Sciences of the United States of America, 82, 3688-3692.
6. Fidler, I. J., Fogler, W. E., Kleinerman, E. S., & Saiki, I. (1985). Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes. Journal of Immunology, 135, 4289-4296.
7. Foster, G. R. (2004). Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology & Therapeutics, 20, 825-830.
8. Gallin, J. L., Farber, J. M., Holland, S. M., & Nutman, T. B. (1995). Interferon-gamma in the management of infectious diseases. Annals Internal of Medicine, 123, 216-224.
9. Herrmann, J., & Stricker, H. (1995). Interferon-γ liposomes: drug binding properties and antiviral in vitro activity. European Journal of Pharmaceutics and Biopharmaceutics, 41, 361-368.
10. Hlady, V., & Buijs, J. (1996). Protein adsorption on solid surfaces. Current Opinion of Biotechnology, 7, 72-77.
11. Hockertz, S., Franke, G., Kniep, E., & Lohmann-Matthes, M. L. (1989). Mouse interferon-γ in liposomes: pharmacokinetics, organ-distribution and activation of spleen and liver macrophages in vivo. Journal of Interferon Research, 9, 591-602.
12. Holland, S. M., Eisenstein, E., & Kuhns, D. B. (1994). Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon-gamma. New England Journal of Medicine, 330, 1348-1355.
13. Hubel, K., Dale, D. C., & Liles, W. C. (2002). Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. Journal of Infectious Disease, 15, 1490-1501.
14. Ishihara, H., Hara, T., Aramaki, Y., Tsuchiya, S., & Hosoi, K. (1991). Interaction of recombinant human interferon-γ with liposomes. Chemical and Pharmaceutical Bulletin, 39, 1536-1539.
15. Jeppson, J. D., Jaffe, H. S., & Hill, H. R. (1991). Use of recombinant human interferon-gamma to enhance neutrophil chemtactic responses in Job syndrome of hyper-immunoglobulin E and recurrent infections. Journal of Pediatrics, 118, 606-614.
16. Le Page, C., Genin, P., Baines, M., & Hiscott, J. (2000). Interferon activation and innate immunity. Reviews in Immunogenetics, 2, 374-386.
17. Lei, H., Ju, D. W., Yu, Y., Tao, Q., Chen, G., Gu, S., Hamada, H., & Cao, X. (2000). Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon gamma. Gene Therapy, 7, 707-713.
18. Merodio, M., Arnedo, A., Renedo, M. J., & Irache, J. M. (2001). Ganciclovir-loaded albumin nanoparticles: characterization and in-vitro release properties. European Journal of Pharmaceutics and Biopharmaceutics, 12, 251-259.
19. Morpurgo, M., & Veronese, F. M. (2004). Conjugates of peptides and proteins to polyethylene glycols. Methods in Molecular Biology, 283, 45-60.
20. Murray, H. W. (1994). Interferon-gamma and host antimicrobial defense: current and future clinical applications. American Journal of Medicine, 97, 459-467.
21. Peters, T. (1985). Serum Albumin. Advances in Protein Chemistry, 37, 161-215.
22. Rinderknecht, E., O'Connor, B. H., & Rodriguez, H. (1984). Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation. Journal of Biological Chemistry, 259, 6790-6797.
23. Saravolac, E. G., Kournikakis, B., Gorton, L., & Wong, J. P. (1996). Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ. Antiviral Research, 29, 199-207.
24. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Olson, B. J., & Klenk, D. C. (1985). Measurement of protein using bicinchoninic acid. Analytical Biochemistry, 150, 76-85.
25. Stoeckle, M. Y., Falk-Pederson, E., Rubin, B. Y., Anderson, S. L., & Murrya, H. W. (1996). Delivery of human interferon-γ via gene transfer in vitro: prolonged expression and induction of macrophage antimicrobial activity. Journal of International Cytokine Research, 16, 1015-1019.
26. van Slooten, M. L., Visser, A. J. W. G., Van Hoek, A., Storm, G., Crommelin, D. J. A., & Jiskoot, W. (2000). Conformational stability of human Interferon-gamma on association with and dissociation from liposomes. Journal of Pharmaceutical Sciences, 89, 1605-1619.
27. van Slooten, M. L., Boerman, O., Romoren, K., Kedar, E., Crommelin, D. J. A., & Storm, G. (2001a). Liposomes as sustained release system for human interferon-γ: biopharmaceutical aspects. Biochimica et Biophysica Acta, 1530, 134-145.
28. van Slooten, M. L., Hayon, I., Babai, I., Zakay-Rones, Z., Wagner, E., Storm, G., & Kedar, E. (2001b). Immunoadjuvant activity of interferon-γ liposomes co-administered with influenza vaccines. Biochimica et Biophysica Acta, 1531, 99-110.
29. Wang, W. (1999). Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 185, 129-188.
30. Wills, R. J. (1990). Clinical pharmacokinetics of interferons. Clinical Pharmacokinetics, 19, 390-399.
31. Yang, J., & Cleland, J. L. (1997). Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-γ) from PLGA microspheres. Journal of Pharmaceutical Sciences, 86, 908-914.
32. Younes, H. M., & Amsden, B. G. (2002). Interferon-γ therapy: evaluation of routes of administration and delivery systems. Journal of Pharmaceutical Sciences, 91, 2-17.
33. Zlateva, T., Boteva, R., Salvato, B., & Tsanev, R. (1999). Factors affecting the dissociation and aggregation of human interferon gamma. International Journal of Biological Macromolecules, 26, 357-362.